PT-141 (Bremelanotide) Pipeline, FDA Approval, and Next-Generation Development

What Is Bremelanotide and How Did It Reach the FDA?

Bremelanotide started life as a sunless-tanning peptide. Researchers at the University of Arizona synthesized Melanotan II in the 1980s, and subjects self-administering the compound unexpectedly reported spontaneous erections and heightened sexual interest. Palatin Technologies subsequently stripped the cyclic heptapeptide down to a hexapeptide scaffold, optimizing receptor selectivity toward MC3R and MC4R while reducing the dermal pigmentation signal tied to MC1R activation. The resulting molecule, bremelanotide (PT-141), was reformulated as an autoinjector and advanced into the RECONNECT Phase III program.

The FDA granted approval under NDA 210557 on June 21, 2019. The agency's review relied on two key randomized, double-blind, placebo-controlled trials published in Obstetrics and Gynecology [1]. That approval made bremelanotide only the second drug approved specifically for HSDD, following flibanserin (Addyi) in 2015.

The RECONNECT Trial Results in Detail

The RECONNECT program enrolled 1,267 premenopausal women across two parallel trials (Study 301 and Study 302) [1]. The primary endpoints were change in the number of satisfying sexual events (SSEs) per 28-day period and change in the Female Sexual Function Index desire domain score, measured using the eDiary and validated questionnaire instruments over 24 weeks.

Bremelanotide 1.75 mg produced a statistically significant increase in SSEs compared to placebo (P<0.001) in both studies [1]. The Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) score also improved significantly. Effect sizes were modest by conventional standards, a point the FDA's medical reviewer noted explicitly during the advisory committee process, but the agency concluded that even a small increase in SSEs represented a clinically meaningful benefit for a patient population with no other on-demand option.

Mechanism: Why Melanocortin Receptors Affect Desire

MC4R is expressed in hypothalamic nuclei, including the paraventricular nucleus and the medial preoptic area, regions that govern sexual motivation in rodent models and, based on neuroimaging data, in humans as well [2]. Agonism at MC4R appears to shift dopaminergic tone in the mesolimbic pathway, increasing appetitive sexual behavior without requiring continuous receptor occupancy. That mechanism is why bremelanotide can be dosed on demand rather than daily, distinguishing it pharmacologically from flibanserin, which requires nightly oral dosing for weeks before effect.

MC3R co-agonism contributes to the nausea and transient blood pressure elevation seen in clinical use, since MC3R is expressed on hypothalamic neurons controlling autonomic outflow [3].

FDA Label: What Prescribers and Patients Must Know

The approved Vyleesi prescribing information specifies a single dose of 1.75 mg administered subcutaneously to the abdomen or thigh approximately 45 minutes before anticipated sexual activity [4]. The label imposes a 24-hour minimum interval between doses and offers no indication for daily use. Patients should not use more than one dose per 24-hour period.

Contraindications and Cardiovascular Warnings

The label carries a contraindication for patients with known cardiovascular disease or uncontrolled hypertension [4]. In the RECONNECT trials, bremelanotide produced a mean maximum increase of approximately 6 mmHg systolic and 3 mmHg diastolic blood pressure, with peak effect at approximately 4 hours post-injection and resolution by 12 hours in most subjects [1]. Prescribers are instructed to avoid use in patients with a history of cardiovascular disease, and to advise patients not to take the drug if their resting blood pressure is elevated at the time of planned dosing.

The FDA's post-market pharmacovigilance program (FDA Sentinel) has flagged no new cardiovascular safety signals through publicly available periodic safety update data as of the 2024 review cycle, though Palatin is obligated to continue submitting annual reports under the NDA's post-marketing commitments [5].

Nausea: The Rate-Limiting Adverse Effect

Nausea is the most frequently reported adverse reaction. Across RECONNECT, approximately 40% of bremelanotide-treated patients reported nausea compared to 1% on placebo [1]. Severity was predominantly mild to moderate. Roughly 13% of patients used antiemetic medication after dosing, and 9% discontinued because of nausea [1]. The label recommends that patients take an antiemetic before injection if prior doses have caused nausea, and Palatin's patient support program includes co-prescribing guidance for ondansetron 4 mg orally 30 minutes before injection.

Flushing, Injection-Site Reactions, and Hyperpigmentation

Facial flushing occurred in approximately 20% of RECONNECT participants [1]. Injection-site bruising and pain were reported in roughly 11% [1]. A distinct concern is focal hyperpigmentation: the label warns that up to 1% of patients may develop persistent darkening of the face, gums, or breasts, attributed to residual MC1R agonism [4]. Patients with darker skin tones appear at higher baseline risk, and the label advises clinicians to counsel this population before prescribing.

Post-Market Surveillance and Real-World Safety Data

Spontaneous Adverse Event Reports (FAERS)

FDA Adverse Event Reporting System (FAERS) data through Q1 2025 show nausea, vomiting, flushing, and injection-site reactions as the dominant signal clusters for bremelanotide, consistent with the trial data [5]. No unexpected hepatotoxicity signals have emerged, which contrasts with flibanserin's post-market experience, where alcohol interaction warnings were strengthened after approval. The melanocortin system does not involve CYP2C19 polymorphisms that complicated flibanserin's safety narrative.

Drug Interaction Profile

Bremelanotide slows gastric emptying transiently, an effect that can reduce oral drug absorption in the 4-hour window after injection [4]. The label specifically flags that co-administration with oral naltrexone or oral indomethacin may reduce systemic exposure of those drugs. Prescribers managing patients on opioid-use disorder treatment with naltrexone should time doses carefully or consider whether bremelanotide is appropriate in that setting.

Long-Term Exposure Data

The RECONNECT open-label extension enrolled a subset of completers and followed them for up to 52 weeks of as-needed use [1]. No new safety signals emerged over long-term follow-up. Hyperpigmentation did not appear to worsen with cumulative exposure in the extension cohort, though the sample size for this sub-analysis was small (N<200 in the extension arm).

How Bremelanotide Compares to Flibanserin

Two drugs are FDA-approved for HSDD in premenopausal women. They differ substantially in mechanism, dosing schedule, adverse event profile, and drug interactions. The table below summarizes the key clinical distinctions prescribers use at the point of care.

| Feature | Bremelanotide (Vyleesi) | Flibanserin (Addyi) | |---|---|---| | Mechanism | MC3R/MC4R agonist | 5-HT1A agonist / 5-HT2A antagonist / D4 partial agonist | | Dosing schedule | On-demand, 45 min before activity | Daily oral, continuous | | Time to effect | 45 minutes | 4-8 weeks continuous | | Alcohol restriction | None | Strict (black box warning) | | Primary AE | Nausea (~40%) | Somnolence, dizziness | | CYP interaction | None significant | CYP3A4 substrate (major) | | FDA approval year | 2019 | 2015 | | Pregnancy category | Contraindicated | Contraindicated |

Clinicians at HealthRX generally reserve bremelanotide for patients who prefer on-demand dosing or who have difficulty tolerating daily medication regimens. Women on strong CYP3A4 inhibitors (such as fluconazole or certain HIV antiretroviral regimens) cannot safely use flibanserin, making bremelanotide the default option in those cases [6].

The MC4R Pipeline: What Comes After Bremelanotide

Next-Generation Melanocortin Agonists in Development

Bremelanotide's nausea burden is tied substantially to MC3R agonism. Preclinical work published in the Journal of Medicinal Chemistry has demonstrated that small-molecule and peptide analogs with greater MC4R selectivity (selectivity ratios above 50-fold over MC3R) produce less emesis in ferret models while retaining pro-sexual behavior in rats [7]. Several pharmaceutical groups are advancing such compounds through IND-enabling toxicology studies.

Palatin Technologies has disclosed pipeline assets targeting melanocortin receptors for additional indications, including dry eye disease (PL9643, a topical MC1R/MC3R agonist with Phase III data), inflammatory conditions, and metabolic disease [8]. These programs demonstrate that the melanocortin scaffold carries utility well beyond sexual function.

Oral and Intranasal Reformulation Research

The subcutaneous route is a barrier for some patients. Oral bioavailability of bremelanotide itself is poor (<5%) because of first-pass peptide degradation. Intranasal administration was studied in early Phase I work at Palatin before the subcutaneous route was selected, and that research established proof-of-concept for mucosal delivery of melanocortin peptides [9]. Lipid nanoparticle formulations that protect cyclic peptides from enzymatic cleavage in the GI tract are an active area in peptide delivery research more broadly, and researchers have proposed applying such platforms to MC4R agonists [10].

Male HSDD and Erectile Dysfunction: Unmet Regulatory Space

Bremelanotide is not FDA-approved for men. Early clinical work at the University of Arizona demonstrated penile erection responses to intranasal Melanotan II in men with psychogenic erectile dysfunction, but Palatin's development program focused entirely on HSDD in premenopausal women for the NDA filing [2]. The male indication remains an investigational space.

A 2021 review in the Journal of Sexual Medicine noted that MC4R agonism may address the central, libido-related component of male sexual dysfunction that PDE5 inhibitors do not treat, since sildenafil and tadalafil act peripherally on vascular smooth muscle without affecting desire or motivation [11]. A combination approach pairing an MC4R agonist with a PDE5 inhibitor has been hypothesized but not yet tested in a registered Phase II trial.

Melanocortin Receptors and Metabolic Crossover

MC4R loss-of-function mutations are the most common monogenic cause of severe human obesity, accounting for roughly 3-5% of extreme obesity cases [12]. Setmelanotide, an MC4R agonist approved by the FDA in November 2020 for POMC, PCSK1, and LEPR deficiency-associated obesity, demonstrates that the same receptor family bremelanotide activates can drive meaningful metabolic outcomes [13]. Setmelanotide produced a mean body weight reduction of 25.6% in a 52-week open-label trial in POMC-deficient patients (N=10) [13].

This metabolic activity raises the question of whether bremelanotide itself has any weight or appetite effect at the approved 1.75 mg dose. The RECONNECT safety data did not capture formal weight endpoints, and no dedicated metabolic sub-study was conducted. At supratherapeutic doses, animal models show appetite suppression via MC4R, but the approved human dose appears to sit below the threshold for meaningful metabolic signaling based on available receptor occupancy modeling [7].

Regulatory Pathway for Future MC4R Indications

NDA vs. SNDA: What Palatin Would Need

Adding a new indication to an existing NDA requires a supplemental New Drug Application (sNDA). For a male HSDD or erectile dysfunction indication, the FDA would almost certainly require at least two adequate and well-controlled Phase III trials with a validated primary endpoint, given the agency's prior insistence on dual-trial evidence for the female HSDD programs [4]. The FDA's guidance on developing drugs for female sexual dysfunction, issued in 2016, applies analogously to male indications and calls for patient-reported outcome instruments validated in the target population [14].

Orphan Drug Designations and Rare Melanocortin Conditions

Setmelanotide holds orphan drug designation for MC4R pathway deficiencies. A bremelanotide-based or next-generation MC4R agonist targeting a distinct rare genetic obesity phenotype could also pursue orphan designation, which provides seven years of market exclusivity post-approval and tax credits on clinical trial costs [15]. This regulatory incentive is one reason smaller biotech companies continue investing in MC4R-selective analogs despite the competitive metabolic drug environment now shaped by GLP-1 receptor agonists such as semaglutide and tirzepatide.

EMA and International Regulatory Status

Bremelanotide does not hold European Medicines Agency (EMA) approval. Palatin did not submit a Marketing Authorization Application in the EU following the FDA approval, citing market access and reimbursement challenges for sexual health indications in European health systems. The absence of an EMA approval means there is no published European Public Assessment Report (EPAR) for bremelanotide. Physicians practicing in the EU who encounter patient inquiries about Vyleesi should clarify that the drug lacks regulatory authorization in their jurisdiction.

Clinical Prescribing Guidance: Practical Points from the Label and Trials

Patient Selection Criteria

The approved indication is restricted to premenopausal women with generalized, acquired HSDD. "Generalized" means the low desire occurs regardless of partner, situation, or type of stimulation. "Acquired" means the condition developed after a period of normal sexual function. The label does not cover postmenopausal HSDD, situational HSDD, or sexual aversion disorder [4]. Clinicians should document DSM-5 HSDD criteria and rule out relationship distress as the primary driver before prescribing.

A screening blood pressure measurement above 130/80 mmHg on the day of prescribing should prompt a conversation about whether the cardiovascular risk profile is acceptable, given the transient pressor effect documented in RECONNECT [1].

Dosing, Storage, and Administration Instructions

Each Vyleesi autoinjector contains 1.75 mg bremelanotide in 0.4 mL solution. Patients inject subcutaneously into the abdomen or thigh 45 minutes before anticipated sexual activity. The autoinjector should be stored at room temperature (below 30°C) and protected from light [4]. Unused autoinjectors can be refrigerated but must be brought to room temperature before injection to minimize injection-site discomfort. Patients should not inject into areas with active skin lesions or tattoos.

Monitoring and Follow-Up

No routine laboratory monitoring is required by the label. Clinicians should ask about hyperpigmentation at follow-up visits, particularly in patients with Fitzpatrick skin types IV through VI who are at higher baseline risk of visible pigmentation changes [4]. If persistent facial or gingival hyperpigmentation develops, discontinuation is recommended and lesions typically, though not always, fade over several months after stopping use.